{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:10:53Z","timestamp":1794978653897,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nile Albright Research Foundation, The Flatley Foundation, The Worden Family Foundation, The Barshad Family."},{"name":"Vincent Memorial Hospital Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bispecific T-cell Engagers (BITEs) are a novel form of immunotherapy that overcome a deficiency of immune checkpoint inhibitors (ICI) by targeting a preidentified tumor associated antigen and redirecting a polyclonal population of effector T-cells against the tumor. High grade serous ovarian cancer is a lethal disease in the recurrent setting and has not been amenable to ICI therapy. MUC16\/CA125 is overexpressed in high grade serous ovarian cancer. BITEs targeting the tumor-retained portion of MUC16\/CA125 have recently been described and are in early-phase clinical trials. To identify mechanisms of resistance to BITEs, we collected serum, peripheral blood mononuclear cells, and ascites samples from patients with disease progression on MUC16-directed bispecific antibodies. Analysis of these samples showed downregulation of MUC16\/CA125, elevated secretion of VEGF, and epithelial-to-mesenchymal transition in tumor cells. Interestingly, hypoxia was determined to be a driver of these changes. These findings were prospectively validated in ovarian cancer cell lines with CRISPR\/Cas9 knockout of MUC16\/CA125 and VEGF. Peripheral blood mononuclear cells from patients with disease progression were capable of effective cytolysis ex vivo, suggesting that resistance to therapy was primarily tumor driven. Restoration of MUC16\/CA125 expression did not restore cytotoxicity in the presence of increased VEGF secretion. Combination treatment with a VEGF inhibitor rescued cytotoxicity in hypoxia-conditioned ovarian cancer cell lines with preserved target antigen expression. Collectively, these data outline a link between hypoxia and the development of resistance to BITEs and posits inhibition of VEGF inhibition as a potentially important therapeutic intervention.<\/jats:p>","DOI":"10.1038\/s41392-025-02505-3","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:02:09Z","timestamp":1766102529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers"],"prefix":"10.1038","volume":"10","author":[{"given":"Mengyao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syem K.","family":"Barakzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irva","family":"Veillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bregar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bouberhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Filipi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpeng","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0911-8254","authenticated-orcid":false,"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3263-0843","authenticated-orcid":false,"given":"Xingping","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-5085","authenticated-orcid":false,"given":"Kristopher","family":"Sarosiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-5658","authenticated-orcid":false,"given":"Cesar","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Spriggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6319-1647","authenticated-orcid":false,"given":"Oladapo O.","family":"Yeku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"2505_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ygyno.2014.01.021","volume":"132","author":"DA Mehta","year":"2014","unstructured":"Mehta, D. A. & Hay, J. W. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. Gynecol. Oncol. 132, 677\u2013683 (2014).","journal-title":"Gynecol. Oncol."},{"key":"2505_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/1097-0215(20000701)87:1<79::AID-IJC12>3.0.CO;2-L","volume":"87","author":"PJ Sabbatini","year":"2000","unstructured":"Sabbatini, P. J. et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int. J. Cancer 87, 79\u201385 (2000).","journal-title":"Int. J. Cancer"},{"key":"2505_CR3","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi, J. et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015\u20134022 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2505_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0460-x","volume":"13","author":"M Koneru","year":"2015","unstructured":"Koneru, M., O\u2019Cearbhaill, R., Pendharkar, S., Spriggs, D. R. & Brentjens, R. J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 13, 102 (2015).","journal-title":"J. Transl. Med."},{"key":"2505_CR5","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2217\/fon-2017-0646","volume":"14","author":"KN Moore","year":"2018","unstructured":"Moore, K. N. et al. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol. 14, 1669\u20131678 (2018).","journal-title":"Future Oncol."},{"key":"2505_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","volume":"5","author":"ML Disis","year":"2019","unstructured":"Disis, M. L. et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 5, 393\u2013401 (2019).","journal-title":"JAMA Oncol."},{"key":"2505_CR7","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/JCO.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi, J. et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J. Clin. Oncol. 39, 3671\u20133681 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2505_CR8","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080\u20131087 (2019).","journal-title":"Ann. Oncol."},{"key":"2505_CR9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","volume":"5","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos, P. A. et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 5, 1141\u20131149 (2019).","journal-title":"JAMA Oncol."},{"key":"2505_CR10","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","volume":"5","author":"JF Liu","year":"2019","unstructured":"Liu, J. F. et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol. 5, 1731\u20131738 (2019).","journal-title":"JAMA Oncol."},{"key":"2505_CR11","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore, K. N. et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J. Clin. Oncol. 39, 1842\u20131855 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2505_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","volume":"182","author":"Z Wu","year":"2018","unstructured":"Wu, Z. & Cheung, N. V. T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics. Pharm. Ther. 182, 161\u2013175 (2018).","journal-title":"Pharm. Ther."},{"key":"2505_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.20908","volume":"115","author":"P Hoffmann","year":"2005","unstructured":"Hoffmann, P. et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct. Int. J. Cancer 115, 98\u2013104 (2005).","journal-title":"Int. J. Cancer"},{"key":"2505_CR14","doi-asserted-by":"crossref","unstructured":"Middelburg, J. et al. Overcoming challenges for CD3-bispecific antibody therapy in solid tumors. Cancers 13, 287 (2021).","DOI":"10.3390\/cancers13020287"},{"key":"2505_CR15","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196\u20131206 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2505_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios, G. et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N. Engl. J. Med. 393, 349\u2013361 (2025).","journal-title":"N. Engl. J. Med."},{"key":"2505_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ygyno.2011.04.032","volume":"121","author":"RC Bast Jr.","year":"2011","unstructured":"Bast, R. C. Jr. & Spriggs, D. R. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol. Oncol. 121, 429\u2013430 (2011).","journal-title":"Gynecol. Oncol."},{"key":"2505_CR18","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/cncr.24084","volume":"115","author":"KK Zorn","year":"2009","unstructured":"Zorn, K. K. et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 115, 1028\u20131035 (2009).","journal-title":"Cancer"},{"issue":"Suppl 3","key":"2505_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1136\/ijgc-00009577-200511001-00015","volume":"15","author":"RC Bast Jr.","year":"2005","unstructured":"Bast, R. C. Jr. et al. New tumor markers: CA125 and beyond. Int. J. Gynecol. Cancer 15(Suppl 3), 274\u2013281 (2005).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2505_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/PAI.0b013e3181dbfcd2","volume":"18","author":"T Dharma Rao","year":"2010","unstructured":"Dharma Rao, T. et al. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. Appl. Immunohistochem. Mol. Morphol. 18, 462\u2013472 (2010).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"2505_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1167\/iovs.05-0735","volume":"47","author":"P Argueso","year":"2006","unstructured":"Argueso, P., Tisdale, A., Spurr-Michaud, S., Sumiyoshi, M. & Gipson, I. K. Mucin characteristics of human corneal-limbal epithelial cells that exclude the rose bengal anionic dye. Invest. Ophthalmol. Vis. Sci. 47, 113\u2013119 (2006).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2505_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663379","volume":"12","author":"OO Yeku","year":"2021","unstructured":"Yeku, O. O. et al. Bispecific T-cell engaging antibodies against MUC16 demonstrate efficacy against ovarian cancer in monotherapy and in combination with PD-1 and VEGF inhibition. Front. Immunol. 12, 663379 (2021).","journal-title":"Front. Immunol."},{"key":"2505_CR23","doi-asserted-by":"crossref","unstructured":"Crawford, A. et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci. Transl. Med. 11, 497 (2019).","DOI":"10.1126\/scitranslmed.aau7534"},{"key":"2505_CR24","doi-asserted-by":"publisher","first-page":"S516","DOI":"10.1016\/j.annonc.2023.09.1933","volume":"34","author":"RE O\u2019Cearbhaill","year":"2023","unstructured":"O\u2019Cearbhaill, R. E. et al. 754P Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study. Ann. Oncol. 34, S516\u2013S517 (2023).","journal-title":"Ann. Oncol."},{"key":"2505_CR25","doi-asserted-by":"crossref","unstructured":"Winer, I. S. et al. 127P REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: phase I dose-escalation study. Immuno-Oncol. Technol. 20 100599 (2023).","DOI":"10.1016\/j.iotech.2023.100599"},{"key":"2505_CR26","first-page":"A9","volume":"33","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. PO011LBA\/#1512; Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results. Int. J. Gynecol. Cancer 33, A9\u2013A10 (2023).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2505_CR27","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","volume":"27","author":"M Taki","year":"2021","unstructured":"Taki, M. et al. Tumor immune microenvironment during epithelial-mesenchymal transition. Clin. Cancer Res 27, 4669\u20134679 (2021).","journal-title":"Clin. Cancer Res"},{"key":"2505_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford, C. E., Werner, B., Hacker, N. F. & Warton, K. The untapped potential of ascites in ovarian cancer research and treatment. Br. J. Cancer 123, 9\u201316 (2020).","journal-title":"Br. J. Cancer"},{"key":"2505_CR29","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/(SICI)1097-0215(19970529)71:5<842::AID-IJC24>3.0.CO;2-8","volume":"71","author":"KO Lloyd","year":"1997","unstructured":"Lloyd, K. O., Yin, B. W. & Kudryashov, V. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule. Int. J. Cancer 71, 842\u2013850 (1997).","journal-title":"Int. J. Cancer"},{"key":"2505_CR30","doi-asserted-by":"publisher","unstructured":"Qin, X. et al. Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X(L) degradation to overcome cancer chemoresistance. Preprint at https:\/\/doi.org\/10.1101\/2025.06.24.661170 (2025).","DOI":"10.1101\/2025.06.24.661170"},{"key":"2505_CR31","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","volume":"4","author":"J Derrien","year":"2023","unstructured":"Derrien, J. et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat. Cancer 4, 1536\u20131543 (2023).","journal-title":"Nat. Cancer"},{"key":"2505_CR32","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody, S. et al. GPRC5D-targeted CAR T cells for myeloma. N. Engl. J. Med. 387, 1196\u20131206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2505_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2505_CR34","doi-asserted-by":"publisher","first-page":"e0126633","DOI":"10.1371\/journal.pone.0126633","volume":"10","author":"TD Rao","year":"2015","unstructured":"Rao, T. D. et al. Expression of the carboxy-terminal portion of MUC16\/CA125 induces transformation and tumor invasion. PLoS ONE 10, e0126633 (2015).","journal-title":"PLoS ONE"},{"key":"2505_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ygyno.2006.07.027","volume":"104","author":"MM Juretzka","year":"2007","unstructured":"Juretzka, M. M. et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol. Oncol. 104, 176\u2013180 (2007).","journal-title":"Gynecol. Oncol."},{"key":"2505_CR36","doi-asserted-by":"publisher","first-page":"868061","DOI":"10.3389\/fonc.2022.868061","volume":"12","author":"Q Wang","year":"2022","unstructured":"Wang, Q., Feng, X., Liu, X. & Zhu, S. Prognostic value of elevated pre-treatment serum CA-125 in epithelial ovarian cancer: a meta-analysis. Front Oncol. 12, 868061 (2022).","journal-title":"Front Oncol."},{"key":"2505_CR37","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1096\/fj.14-257352","volume":"28","author":"D Haridas","year":"2014","unstructured":"Haridas, D. et al. MUC16: molecular analysis and its functional implications in benign and malignant conditions. FASEB J. 28, 4183\u20134199 (2014).","journal-title":"FASEB J."},{"key":"2505_CR38","doi-asserted-by":"publisher","first-page":"e4675","DOI":"10.1371\/journal.pone.0004675","volume":"4","author":"DJ Cheon","year":"2009","unstructured":"Cheon, D. J. et al. CA125\/MUC16 is dispensable for mouse development and reproduction. PLoS ONE 4, e4675 (2009).","journal-title":"PLoS ONE"},{"key":"2505_CR39","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41588-020-0630-5","volume":"52","author":"A Jimenez-Sanchez","year":"2020","unstructured":"Jimenez-Sanchez, A. et al. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat. Genet. 52, 582\u2013593 (2020).","journal-title":"Nat. Genet."},{"key":"2505_CR40","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","volume":"170","author":"A Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez, A. et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170, 927\u2013938.e920 (2017).","journal-title":"Cell"},{"key":"2505_CR41","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","volume":"612","author":"I Vazquez-Garcia","year":"2022","unstructured":"Vazquez-Garcia, I. et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612, 778\u2013786 (2022).","journal-title":"Nature"},{"key":"2505_CR42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0090-8258(89)90628-8","volume":"32","author":"W Neunteufel","year":"1989","unstructured":"Neunteufel, W. & Breitenecker, G. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA. Gynecol. Oncol. 32, 297\u2013302 (1989).","journal-title":"Gynecol. Oncol."},{"key":"2505_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06583-3","volume":"23","author":"S Bakrim","year":"2025","unstructured":"Bakrim, S. et al. Targeting inflammation in cancer therapy: from mechanistic insights to emerging therapeutic approaches. J. Transl. Med. 23, 588 (2025).","journal-title":"J. Transl. Med."},{"key":"2505_CR44","first-page":"456","volume":"64","author":"M Bickel","year":"1993","unstructured":"Bickel, M. The role of interleukin-8 in inflammation and mechanisms of regulation. J. Periodontol. 64, 456\u2013460 (1993).","journal-title":"J. Periodontol."},{"key":"2505_CR45","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2326-6066.CIR-23-0145","volume":"11","author":"IM Stromnes","year":"2023","unstructured":"Stromnes, I. M. IL18 at the crossroads between chronic inflammation and T-cell exhaustion in pancreatic cancer. Cancer Immunol. Res 11, 400 (2023).","journal-title":"Cancer Immunol. Res"},{"key":"2505_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107765","volume":"96","author":"M Ghanbari","year":"2021","unstructured":"Ghanbari, M. et al. Interleukin-1 in obesity-related low-grade inflammation: From molecular mechanisms to therapeutic strategies. Int. Immunopharmacol. 96, 107765 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"2505_CR47","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/bjc.2011.34","volume":"104","author":"M Comamala","year":"2011","unstructured":"Comamala, M. et al. Downregulation of cell surface CA125\/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br. J. Cancer 104, 989\u2013999 (2011).","journal-title":"Br. J. Cancer"},{"key":"2505_CR48","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1158\/0008-5472.CAN-19-2306","volume":"80","author":"A Miar","year":"2020","unstructured":"Miar, A. et al. Hypoxia induces transcriptional and translational downregulation of the type I IFN pathway in multiple cancer cell types. Cancer Res. 80, 5245\u20135256 (2020).","journal-title":"Cancer Res."},{"key":"2505_CR49","doi-asserted-by":"publisher","first-page":"e0187314","DOI":"10.1371\/journal.pone.0187314","volume":"12","author":"S Sethumadhavan","year":"2017","unstructured":"Sethumadhavan, S. et al. Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells. PLoS ONE 12, e0187314 (2017).","journal-title":"PLoS ONE"},{"key":"2505_CR50","first-page":"46","volume":"8","author":"X Cheng","year":"2025","unstructured":"Cheng, X. et al. Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance. Cancer Drug Resist. 8, 46 (2025).","journal-title":"Cancer Drug Resist."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02505-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02505-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:02:11Z","timestamp":1766102531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02505-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2505"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02505-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.O.Y. reports grants from Ascendis Pharma A\/S, Immunocore Limited, Duality Biologics, Merck Sharp & Dohme Corporation, ProfoundBio, and the Department of Defense. Consulting fees from Aadi Bioscience. Advisory board role at hC Bioscience. In addition, he has a patent pending for MUC16 Directed Antibodies for therapeutic applications, and a patent pending for Human Artificial Chromosomes for therapeutic applications. D.R.S. is a co-inventor of the MUC16ecto antibody 4H11 and the patent is held jointly by Memorial Sloan Kettering Cancer Center and Eureka Therapeutics. A patent application has been filed for the modified human 4H11 antibody. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients were consented to the Mass General Brigham Institutional Review Board approved biobanking protocol 07-049 and all experiments were performed under the Mass General Brigham Institutional Review Board approved Excess Human Material secondary use protocol 2019P003362. All experiments were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}}],"article-number":"405"}}